Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psoriasis Vulgaris Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Decision-Framing in Psoriasis

NCT04136314
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriatic Arthritis, Psoriasis
Interventions
Decision-Framed Survey
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

NCT00287547
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
CTLA4Ig / Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
10
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Tofacitinib Ointment For Chronic Plaque Psoriasis

NCT01831466
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 4 Interventional Results available

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NCT00924950
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

NCT07426120
View directory record Official record
Conditions
Psoriasis Vulgaris, Topical Administration, Phase III
Interventions
Total coumarin (TC) cream, Vehicle cream
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

NCT00601107
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Doxercalciferol, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

NCT02125279
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcitriol
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Burbank, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Topical SGX302 for Mild-to-Moderate Psoriasis

NCT05442190
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Hypericin, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris

NCT00235625
View directory record Official record
Conditions
Psoriasis
Interventions
Curcuminoids C3 Complex®
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug · Other
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
30
States / cities
Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

NCT01707043
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Taclonex
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

NCT03322137
View directory record Official record
Conditions
Pruritus, Psoriasis Vulgaris
Interventions
SNA-120, Vehicle
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1 Interventional

Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.

NCT00220025
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Phototherapy
Device
Lead sponsor
Mary Sullivan-Whalen
Other
Eligibility
14 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

NCT05102474
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Polysomnography (PSG)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

NCT06042647
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Phase 4 Interventional

Psoriatic Immune Response to Tildrakizumab

NCT05390515
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Tildrakizumab Prefilled Syringe
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

NCT03308799
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 cream, Cal/BDP combination, Cream vehicle
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Fridley, Minnesota • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

NCT03462927
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 Cream, CAL/BDP combination
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Sweetwater, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
(CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Blue Light Phototherapy

NCT04343586
View directory record Official record
Conditions
Grover's Disease, Psoriasis Vulgaris
Interventions
Blue light phototherapy
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene/betamethasone gel and ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jul 24, 2026, 1:07 AM EDT